City of Dallas × Blue Cross and Blue Shield of Texas (HCSC) / Prime Therapeutics

What they got right

• Lowest-of adjudication logic on compounds and standard claims — the negotiated rate, the MAC price or usual-and-customary, whichever is lowest, applies.
• A written audit-scope list that names rebate credit measurement, MAC pricing accuracy, invoices, eligibility, mail and specialty fulfilment, and manufacturer payments.
• Rebate-guarantee shortfalls payable dollar-for-dollar within roughly 120–150 days of contract year end, per the RFP confirmations.
• Termination for convenience without lost-profit claims.
• A low visible administrative fee — though a low visible fee is usually the tell, not the win.

What they got wrong

1. 1. The waiver behind the promise

   Exhibit B promises "the greater of the minimum Rebate guarantees… or 100% of all Rebates collected." The executed agreement then provides a fixed per-employee-per-month rebate credit paid "from Claim Administrator's own assets notwithstanding the actual amount of rebates," with the city agreeing it has no right to, or legal interest in, any portion of the rebates under either the pharmacy or the medical benefit. Credits end at termination. The precedence clause makes the contract control over the proposal, so the promise in the proposal is not the deal.

2. 2. Pre-leaked rebate definition

   Rebates are defined to exclude manufacturer administration fees and fees retained by a group purchasing organization for its role in securing rebates. Both happen upstream of the defined term, so fixing the pass-through alone would not recover them. This is the exact leak that the CalPERS and Georgia manufacturer-payments definitions are drafted to close.

3. 3. Audit as toll booth

   Rebate audits once per twelve months, onsite at the group purchasing organization in St. Louis, by an auditor who must be mutually approved and separately approved by that same GPO, under the GPO's non-disclosure agreement, with a $15,000 audit fee charged to the city. Affiliate-ownership disclosure only on request, once per calendar year.

4. 4. Vendor-controlled MAC

   The MAC list is defined as the list of unit prices established by Prime, maintained by Prime and updated from time to time. No sponsor approval, no cap on increases, and no duty to reflect all-source acquisition discounts.

5. 5. Exit forfeiture

   Early termination — including under the city's own termination rights — voids the network discount and minimum rebate guarantees for that guarantee period.

6. 6. Vendor-designated specialty

   Specialty is defined as a pharmacy designated by the claim administrator or PBM, leaving both drug classification and dispensing channel with the vendor.

Cost of not fixing it

Order-of-magnitude only, and stated so a reader can disagree with the inputs: roughly 13,000 employees and 30,000 lives, gross pharmacy spend of $40–55M/yr, and brand rebate plus manufacturer-fee value on a book that size of plausibly $10–18M/yr.

Clause by clause

What to ask for at the first amendment window

1. Strike the rebate-credit waiver and restore greater-of-guarantees-or-100%-of-actuals, on an all-remuneration definition, across pharmacy and medical.
2. Redefine rebates to include manufacturer administration fees and GPO retention — without this, fixing the pass-through still leaves the upstream skim intact.
3. Require sponsor approval of MAC changes, with a cap on increases.
4. Audit: city-selected auditor, no GPO approval right, no audit fee, remote data production.
5. Delete the forfeiture of guarantees on early termination.
6. Move specialty designation to a sponsor-approved list.

Every one of these already appears in another public body's agreement — see the clause comparison. That is the point of the comparison: none of it is a novel ask.